

Progenitor Endothelial Cell Dysfunction in Heart Failure: Clinical Implication and Therapeutic Target?

Alexander E Berezin*

Internal Medicine Department, State Medical University of Zaporozhye, Ukraine

*Corresponding author: Alexander E Berezin, Internal Medicine Department, State Medical University of Zaporozhye, UA-69035, Ukraine, Tel: +380612894585; E-mail: dr_berezin@mail.ru

Received date: May 09, 2016; Accepted date: May 17, 2016; Published date: June 01, 2016

Copyright: © 2016 Berezin AE, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.

Abstract

Chronic heart failure (HF) is a leading clinical and public problem affected higher risk of morbidity and mortality in different population. There is emerging evidence regarding that the epigenetic regulation may have a clue in the pathogenesis of HF. Epigenetic modifications including DNA methylation, ATP-dependent chromatin remodeling, histone modifications, and microRNA-related mechanisms, may involve in the endothelium reparation and injury through mobbing and differentiation of endothelial progenitor cell (EPCs). Recent clinical studies have shown that cardiovascular risk may contribute to epigenetic regulation of structure and functionality of EPCs leading to EPCs' dysfunction and worsening of endothelium repair. The short commentary is represented current available evidence regarding an implication of epigenetic modifications in development of EPC dysfunction and its importance for use as a target for HF treatment.

Keywords: Heart failure; Epigenetic modifications; Endothelium; Endothelial progenitor cell dysfunction; Prediction

Short commentary

Endothelial cell dysfunction plays a pivotal role in the pathogenesis of heart failure (HF) [1]. In HF patients there is a sufficient difference between presentation of CV risk factors in HF with reduced left ventricular ejection fraction (HFrEF) and HF with preserved left ventricular ejection fraction (HFpEF) [2-4]. Various molecular and cellular mechanisms are involved in the development and progression of both HF phenotypes [5-7]. There is emerging evidence regarding that the epigenetic regulation may take an important part in the pathogenesis of HF playing a pivotal role in phenotypic response of failing heart [8].

Epigenetics is defined as emerging changes in the regulation of gene activity and expression that are not dependent on gene sequence [9]. Epigenetic modifications affected DNA methylation, ATP-dependent chromatin remodeling, histone modifications, and microRNA-related mechanisms are considered a sufficient factor contributing to adverse cardiac remodeling and preceding cardiac dysfunction [10]. Indeed, DNA hypermethylation have been associated with various CV diseases including HF [11,12], histone post-translational modifications have also been implicated in atherosclerosis, endothelial dysfunction, inflammation, HF [13-15], ATP-dependent chromatin remodeling and microRNA-related mechanisms are necessary of cardiomyopathies, endothelial dysfunction and HF [16].

Recent studies have confirmed the CV risk factor may impact negatively on number and functionality of circulating bone marrow-derived endothelial progenitor cells (EPCs) [17-20]. Moreover, there is evidence regarding a relationship between decreased number of EPCs and the risk of HF advance and occurring HF outcomes [21,22]. The changes in number and functionality of EPCs originated from bone marrow and circulating mononuclear progenitors in CV disease have

recently defined as an “impaired phenotype” of EPCs [19,23]. It has deemed that “impaired phenotype” of EPCs might appear prior to cardiac dysfunction and relates to CV risk factors mediating being a specific setting “incompetence” in endogenous reparation affected endothelium.

Focusing on current insight into the cellular and molecular mechanisms underlying EPC dysfunction, it has suggested that CV risk links CV disease development through epigenetic modifications of EPCs [14]. Indeed, epigenetic modulation of adhesion molecules in endothelial cells regulates the aggregation and adhesion of leukocyte to the vessel wall [24]. Moreover, the effect is induced by inflammatory signals, thrombomodulin, and low-density lipoproteins [24, 25]. Probably, microRNAs as triggered signal transducers might play a pivotal role in the cross-talk regulation among epigenetic factors and repair capability of endothelial progenitor cells [26]. Whether altered signature of miRNA, DNA methylation, ATP-dependent chromatin remodeling, and histone modifications are considered a clue for cardiac hypertrophy and dysfunction, low number of direct clinical evidence regarding specifically endothelial dysfunction development relating to epigenetic modulation remains a part of scientific discussion [27]. However, there is a large body of evidence that post-transcriptional regulation of endothelial nitric-oxide synthase plays a central role in redox signaling, injury of endothelial cells, and worsening of reparative capability of EPCs [28-32].

Whether progenitor endothelial cell dysfunction can improve CV risk prediction, HF risk development and be useful as predictive biomarker in patients with known HF is yet not completely clear. However, understanding the central role of endothelium repair system may provide novel insights into pathophysiology of HF [33]. Although several drugs might regulate the various epigenetic mechanisms in the target cells including EPCs in HF (angiotensin-converting enzyme inhibitors, mineralocorticoid antagonists, angiotensin-receptor/neprilysin inhibitors), the clinical significance of similar approaches are not fully defined due to serious limitation of obtained data and it

has been continued to be under active investigations. All these findings open the novel possibilities for the HF prevention and appear to be promised for target therapy of the HF in future.

In conclusion, the clinical implications of progenitor endothelial cell dysfunction in HF require more investigations in large clinical studies. The molecular regulators of epigenetic modifications as a novel therapeutic target for restoring endothelial cell function in HF is promising aim for primary and secondary endothelial therapy.

References

1. Landmesser U, Drexler H (2005) The clinical significance of endothelial dysfunction. *Curr Opin Cardiol* 20: 547-551.
2. Jorge AL, Rosa ML, Martins WA, Correia DM, Fernandes LC, et al. (2016) The Prevalence of Stages of Heart Failure in Primary Care: A Population-Based Study. *J Card Fail* 22: 153-157.
3. Nichols GA, Reynolds K, Kimes TM, Rosales AG, Chan WW(2015) Comparison of Risk of Re-hospitalization, All-Cause Mortality, and Medical Care Resource Utilization in Patients With Heart Failure and Preserved Versus Reduced Ejection Fraction. *Am J Cardiol* 116: 1088-1092.
4. Berezin AE (2016) Prognostication in different heart failure phenotypes: the role of circulating biomarkers. *J Circulating Biomarkers* 5.
5. Mollova MY, Katus HA, Backs J (2015) Regulation of CaMKII signaling in cardiovascular disease. *Front Pharmacol* 6: 178.
6. Di Salvo TG, Haldar SM (2014) Epigenetic mechanisms in heart failure pathogenesis. *Circ Heart Fail* 7: 850-863.
7. Napoli C, Grimaldi V, De Pascale MR, Sommesse L, Infante T, et al. (2016) Novel epigenetic-based therapies useful in cardiovascular medicine. *World J Cardiol* 8: 211-219.
8. Marín-García J, Akhmedov AT (2015) Epigenetics of the failing heart. *Heart Fail Rev* 20: 435-459.
9. Romanoski CE, Glass CK, Stunnenberg HG, Wilson L, Almouzni G (2015) Epigenomics: Roadmap for regulation. *Nature* 518: 314-316.
10. Berger SL, Kouzarides T, Shiekhattar R, Shilatifard A (2009) An operational definition of epigenetics. *Genes Dev* 23: 781-783.
11. Cao Y, Lu L, Liu M, Li XC, Sun RR, et al. (2014) Impact of epigenetics in the management of cardiovascular disease: a review. *Eur Rev Med Pharmacol Sci* 18: 3097-3104.
12. Movassagh M, Choy MK, Knowles DA, Cordeddu L, Haider S, et al. (2011) Distinct epigenomic features in end-stage failing human hearts. *Circulation* 124: 2411-2422.
13. Roberts AC, Porter KE (2013) Cellular and molecular mechanisms of endothelial dysfunction in diabetes. *Diab Vasc Dis Res* 10: 472-482.
14. Gimbrone MA Jr, García-Cardena G (2016) Endothelial Cell Dysfunction and the Pathobiology of Atherosclerosis. *Circ Res* 118: 620-636.
15. Grimaldi V, Vietri MT, Schiano C, Picascia A, De Pascale MR, et al. (2015) Epigenetic reprogramming in atherosclerosis. *Curr Atheroscler Rep* 17: 476.
16. Duygu B, Poels EM, da Costa Martins PA (2013) Genetics and epigenetics of arrhythmia and heart failure. *Front Genet* 4: 219.
17. Berezin AE, Kremzer AA, Martovitskaya YV, Berezina TA, Gromenko EA (2016) Pattern of endothelial progenitor cells and apoptotic endothelial cell-derived microparticles in chronic heart failure patients with preserved and reduced left ventricular ejection fraction. *EBioMedicine* 4: 86-94.
18. Berezin AE, Kremzer AA, Samura TA, Berezina TA, Martovitskaya YV (2014) Serum uric Acid predicts declining of circulating proangiogenic mononuclear progenitor cells in chronic heart failure patients. *J Cardiovasc Thorac Res* 6: 153-162.
19. Berezin AE, Kremzer AA (2013) Analysis of Various Subsets of Circulating Mononuclear Cells in Asymptomatic Coronary Artery Disease. *J Clin Med* 2: 32-44.
20. Berezin AE, Kremzer AA (2014) Relationship between circulating endothelial progenitor cells and insulin resistance in non-diabetic patients with ischemic chronic heart failure. *Diabetes Metab Syndr* 8: 138-144.
21. Berezin AE, Kremzer AA, Martovitskaya YV, Berezina TA, Samura TA (2016) The utility of biomarker risk prediction score in patients with chronic heart failure. *Clin Hypertens* 22: 3.
22. Berezin AE, Kremzer AA, Samura TA, Martovitskaya YV, Malinovskiy YV, et al. (2015) Predictive value of apoptotic microparticles to mononuclear progenitor cells ratio in advanced chronic heart failure patients. *J Cardiol* 65: 403-411.
23. Berezin A (2014) Serum uric acid as a metabolic regulator of endothelial reparative processes in heart failure patients. *Stem Cell Transl Inv* 1: 1-5.
24. Fang F, Chen D, Yu L, Dai X, Yang Y, et al. (2013) Proinflammatory stimuli engage Brahma related gene 1 and Brahma in endothelial injury. *Circ Res* 113: 986-996.
25. Kumar A, Kumar S, Vikram A, Hoffman TA, Naqvi A, et al.(2013) Histone and DNA methylation-mediated epigenetic downregulation of endothelial Kruppel-like factor 2 by low-density lipoprotein cholesterol. *Arterioscler Thromb Vasc Biol* 33: 1936-1942.
26. Zhang E, Wu Y (2013) MicroRNAs: important modulators of oxLDL-mediated signaling in atherosclerosis. *J Atheroscler Thromb* 20: 215-227.
27. Handy DE, Castro R, Loscalzo J (2011) Epigenetic modifications: basic mechanisms and role in cardiovascular disease. *Circulation* 123: 2145-2156.
28. Margueron R, Reinberg D (2010) Chromatin structure and the inheritance of epigenetic information. *Nat Rev Genet* 11: 285-296.
29. Robb GB, Carson AR, Tai SC, Fish JE, Singh S, et al. (2004) Post-transcriptional regulation of endothelial nitric-oxide synthase by an overlapping antisense mRNA transcript. *J Biol Chem* 279: 37982-37996.
30. Tai SC, Robb GB, Marsden PA (2004) Endothelial nitric oxide synthase: a new paradigm for gene regulation in the injured blood vessel. *Arterioscler Thromb Vasc Biol* 24: 405-412.
31. Shi Y, Whetstine JR (2007) Dynamic regulation of histone lysine methylation by demethylases. *Mol Cell* 25: 1-14.
32. Kim GH, Ryan JJ, Archer SL (2013) The role of redox signaling in epigenetics and cardiovascular disease. *Antioxid Redox Signal* 18: 1920-1936.
33. Park KH, Park WJ (2015) Endothelial Dysfunction: Clinical Implications in Cardiovascular Disease and Therapeutic Approaches. *J Korean Med Sci* 30: 1213-1225.